Pharmatalkradio

This 4 minute podcast summarizes what you can expect at the 6th annual Mobile in Clinical Trials conference. This event provides sessions on the latest progress in applying mobile applications and patient-facing technologies to connect and empower patients, while obtaining better outcomes in drug development. The conference takes place September 16, 2019 at the Renaissance Boston Waterfront Hotel, Boston, MA. The program is co-chaired by Bayer’s Michelle Shogren, Director of Innovation, Pharma R&D Clinical Operations and Healthmode’s Dr. Dan Karlin, CEO. For more information please visit www.theconferenceforum.org or contact us at service@tcfllc.org

An Insight into Our Possible Future Faster than You Think This keynote session was presented at the 2018 DPharm conference. Estonia is now a digital republic with a virtual government, blockchained and secure. Our keynote guest from Estonia tells us how Estonia became the fastest country in the world to go digital. Its 1.3 million citizens pay with their mobile phones, have their health records stored in the digital cloud, and filed their annual tax return online in five minutes. This session demonstrates how Estonian citizens have come to own their personal health records, how doctors have to get their permission to use these records, and how patients choose their own medications digitally. We also learn about their challenges, policies, and of course their vision for digital clinical trials. Speakers: Indrek Onnik, Program Manager, E-Estonia Showroom, a partner of the Estonian Government The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferencef

In this session presented at the 2018 DPharm conference, Rob Goodwin and Amy Nordo share an exciting new collaboration - including industry and academia, as well as health authorities and leading technologists - positioned to break through the barriers to allow the power and the promise of eSource across companies and medical centers. The potential for eSource has been discussed for years, but realizing its promise has been difficult. While most health data today can be captured within electronic health records, the diversity of systems across medical centers and around the world coupled with a lack of health data interoperability has limited our ability to source clinical trial data from existing electronic systems across thousands of investigator sites supporting trials globally. Speakers: Rob Goodwin, VP, Operations Center of Excellence, Global Product Development, Pfizer, Inc. Amy Nordo, Program Director, Duke Center for Healthcare Informatics The 9th annual DPharm conference will take place Septembe

In this podcast from DPharm 2018, Pfizer's VP of Clinical Supply Chain, Michael Ku, speaks about some of Pfizer's earliest work making blockchain real as well as some of their forward-leaning work digitizing supply chain for clinical trials. The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.

In this podcast from DPharm 2018, Bayer shares how they use virtual assistants and chatbots to support study teams, research sites, and patients. Learn how they are doing this and what you should consider. Speaker: Michelle Shogren, Head of Innovation, Portfolio & Operations, Bayer The 9th annual DPharm conference will take place on September 17-18 in Boston, MA. Learn more at theconferenceforum.org.

In this podcast, Valerie Bowling, Director of DPharm, walks you through what to expect at DPharm 2019 in under 5 minutes. This is the 9th annual DPharm conference featuring keynotes from: Dr Scott Gottlieb, 23rd Commissioner of the FDATakeda’s CMO, Dr Andy PlumpMerck’s VP of Global Operations, Dr Mark TraversCellarity's Chief Data Officer, Milind KamkolkarStarbucks' Design Director of Global Digital Products, Robert MercerFast Company's Deputy Editor, David LidskyHealthgrades' Founder, Kerry HicksRadio City Rockette and Patient Advocate, Alyssa Epstein All of this plus: pharma reporting from the trenches, multiple track choices, opportunities to meet patients, and more. The 9th annual DPharm will take place on September 17-18 in Boston, MA. Learn more at theconferenceforum.org

Trialspark, CEO, Dr Ben Liu recently sat down with Valerie Bowling, Executive Director of DPharm in a podcast discussion.  Valerie checked in with Ben on the progress of life as a data science entrepreneur. They also discussed how Ben and his team are solving big challenges in drug development, new evolving R&D models and more. On Sept 17th, Ben will be interviewing Pfizer's Rod Mackenzie, Chief Development Officer at DPharm: Disruptive Innovations to Advance Clinical Trials in Boston. For more information, please visit theconferenceforum.org

When developing technologies to solve medical problems, one often encounters significant hurdles, that at times seems insurmountable. In this discussion, recorded at the 8th annual Partnership Opportunities in Drug Delivery (PODD) conference, Dr Jeffrey Karp, Professor of Medicine, Harvard Medical School and Director of the Laboratory for Accelerated Medical Innovation, Brigham and Women's Hospital discusses overcoming these hurdles with the use of nature for inspiration. This talk will explore medical technologies being developed that harness lessons from nature for inspiration. Some of the technologies that will be described are rapidly advancing to the clinic and some are already on the market helping patients. Join us for the 9th annual PODD conference business development event on October 7-8, 2019 at the Renaissance Boston Waterfront Hotel in Boston. PODD covers the latest advances in drug delivery science, while also providing a meeting place to network and form new partnerships. To learn more about

In this industry keynote recorded at the 8th annual Partnership Opportunities in Drug Delivery (PODD) conference, Justin Wright, PhD, Global Head of Innovation, Novartis, discusses how the transformation from traditional drugs to next-generation product systems, where sometimes the drug is only a component of the overall product offering, is creating a opportunity for non-traditional competitors and start-ups to access the market and potentially redefine the value model associated with drug pricing. To stay competitive, the pharmaceutical industry’s current business model needs to evolve rapidly from a reactive to a prevention model. At the core of this type of evolved model will be a dynamic patient interface with extraordinary patient engagement. And the delivery system will undoubtedly be a key enabler in the process. Dr Wright reviews the current and future state with his perspective and cases studies to help shed light on the key areas where focus is needed focus and corresponding opportunities lie. J

In this podcast from DPharm 2018, Chip Bell shows pragmatic ways to change our culture to support service-oriented thinking that benefits patients and investigators. The patient's expectations are being quickly changed today by disruptors far beyond the Pharma industry. How will the concept of service make us better at drug development and help us become more disruptive thinkers? Speaker: Chip Bell, PhD, Keynote Innovative Service Speaker, Author, Senior Partner, The Chip Bell Group The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.

Moderated by Marian Gindy, PhD, Executive Director, Discovery Pharmaceutical Sciences, Merck, this panel discussion recorded at the 8th annual Partnership Opportunities in Drug Delivery (PODD) conference explores how mRNA vaccines represent a promising alternative to conventional vaccine approaches for infectious diseases as well as oncology indications, including an emerging application for personalized cancer vaccines. The panelists for the session are: Örn Almarsson, PhD, Head of Formulations, Moderna TherapeuticsDanilo Casimiro, PhD, VP and Head, External R&D and Vaccine Platforms, SanofiChristian W Mandl, PhD, MD, Chair, Scientific Advisory Board and Co-Founder, Tiba BiotechJinJun Shi, PhD, Associate Professor, Harvard Medical School and Faculty Member, Center for Nanomedicine at Brigham and Women’s HospitalSybil Williams, PhD, Senior Principal Scientist, Personalized Cancer Biology Lead, Merck Save the date for the 9th annual PODD business development event on October 7-8, 2019 at the Renaissance B

This session was presented at the 8th annual DPharm conference in September 2018. When Amazon announced that the creation of a new healthcare company with Berkshire Hathaway and JPMorgan Chase, the move signaled how the company is stepping into the healthcare industry. However, Amazon Web Services (AWS) has been working directly with the healthcare and life science industries for quite some time. Life Science Director, Mark Johnston, shares how AWS thinks about innovation, in particular for the life science industry, including clinical trials. More specifically: How AWS looks at problems and transforms processes through new technologiesHow to think about going faster to be more effective in solving problems without the worries of infrastructureHow to imagine what to do next if you were un-trapped by historical baggage and preceived limitationsOpportunities to considerExamples Speaker: Mark Johnston, Director of Global Business Development for Health Care, Life Sciences, and Agricultural Technology, Amazon W

Roughly, 5.7 million people in the U.S. are living with Alzheimer’s. Globally, an estimated 47 million individuals are living with dementia. There is no cure, and treatments can only relieve certain symptoms for some people. Research studies so far have a poor record. Patients can face incredible enrollment hurdles in clinical trials.  A Patient Registry can be very useful in identifying patients. A registry can also address the original problem statement about failed trials. A robust, living registry becomes a data pool from which we can improve both drug discovery, using probabilistic statistics and AI/ML to identify new drug candidates, and drug development, using simulators to predict likelihood of success in Phase 2 or 3. In this podcast, we discuss major challenges facing developers of Alzheimer’s therapies and address patient registries and how they can improve enrollment and trial design. In this podcast, we will hear some details about the HealthyMindsRegistry, Synexushmr.com and the Protect Study

This 8 minute podcast summarizes what you can expect at the 4th annual IO Combinations 360° conference. This conference provides the latest data impacting immuno-oncology combinations and patient treatment with perspectives from science, clinical and business. The conference takes place June 20-21, 2019 at the Wyndham Philadelphia Historic District, Philadelphia, PA. For more information please visit www.theconferenceforum.org or contact us at service@tcfllc.org

Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies (CCI), Perelman School of Medicine, University of Pennsylvania focuses on the next steps for CAR-T therapy for cancer, discussing the novel approaches that are being developing in Dr Carl June’s lab including CAR-T combinations with small molecules and gene-editing. Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City. 

The hardest thing to figure out now is what interventions and combinations make the most sense in which patients and how to combine all these emerging modalities in a way that is cost effective, benefits patients and unfolds in our lifetime. There are hypothesis on what technologies should be explored together, however very few companies have all the relevant skills, reagents or product candidates in one setting, so it requires collaboration to generate the most powerful combinations and sequence of interventions. This overview talk, followed by a panel will delve into the following: What is the underlying pathobiology and how it is similar from patient to patient and how it is different in individuals?What interventions make the most sense and how to get the right patient into the studies to test your hypothesis?How can we build an integrated suite of tools to ask and answer all the  relevant questions to appropriately characterize patients?How can we develop something cost effective that doesn’t necessarily

In this panel, moderated by Dr Axel Hoos, GSK, individuals from large pharma and biotech business development leads discuss decision-making when it comes to partnering and collaborations in today’s IO environment. What is the current nature and types of partnerships being done in IO?Is dealmaking and partnerships evolving due to the need for IO combinations? How so?What is the balance between in house R&D and external innovation in IO?What is the decision making regarding exclusive licensing and “no strings attached” partnerships? Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City. 

This panel, moderated by Dr Priti Hegde, Genentech, discusses the following: How can biomarkers act as a tool for understanding the biology at a level that is sufficient for making decisions around combinations?What are the potential biomarkers that can help predict if a patient will respond to combinations?Once a biomarker is identified in terms of biology, been measured and the technology platform identified to meet those measures, how is the biomarker developed to the level of clinical grade that meets approval?How do we validate diagnostics in IO/combinations?How do you satisfy regulators?Are there other biomarkers in development?What are the implications for intervention?Are biomarkers and companion diagnostics crucial for rational combination success? Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City. 

In this podcast, Dr Gregory Goldmacher, Executive Director, Translational Biomarkers and Head of Clinical Imaging, Merck Research Labs along with Dr Matthew Silva, Executive Vice President, Scientific Applications, Invicro discuss innovations in IO imaging.   Together, Dr Goldmacher and Dr Silva address: The evolution of treatment response criteria in immuno-oncologyNovel Tracers: Monitoring tumor or immune cell populations with imagingRadiomics, AI and Digital Biomarkers Join us February 26-28, 2020 in NYC for the 6th annual Immuno-Oncology 360° Summit where we will continue to expand on imaging aspects for cancer immunotherapy. To learn more visit www.theconferenceforum.org

The 2nd annual Drug Delivery West (DDW) Summit provides a west coast venue for biotech, pharma and drug delivery companies to address scientific and business solutions for the best routes of delivery across different therapeutic areas with an emphasis on emerging technologies and to prepare for the future of R&D and clinical care. This podcast discusses who will be presenting and the topics covered at the summit taking place May 6-7, 2019 at the Marines' Memorial Club and Hotel in San Francisco, CA